Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 13 January

Jessica Amir
January 13, 2021

Morning Bell 12 January

Jessica Amir
January 12, 2021

Morning Bell 11 January

Jessica Amir
January 11, 2021

Morning Bell 8 January

Paulina Peters
January 8, 2021

Morning Bell 7 January

Paulina Peters
January 7, 2021

Morning Bell 6 January

Paulina Peters
January 6, 2021

Morning Bell 5 January

Jessica Amir
January 5, 2021

Morning Bell 4 January

Jessica Amir
January 4, 2021

Morning Bell 30 December

Jessica Amir
December 30, 2020

Morning Bell 29 December

Jessica Amir
December 29, 2020

Morning Bell 24 December

Jessica Amir
December 24, 2020